Table 1.
Baseline characteristics of all patients
| Variable | Value | % |
|---|---|---|
| Female, n/n (%) | 7518/17 162 | 43.8 |
| Age, mean (SD) (years) | 69.8 (11.4) | n/a |
| Age group, n/n (%) | ||
| <65 years | 5094/17 162 | 29.7 |
| 65–69 years | 2506/17 162 | 14.6 |
| 70–74 years | 3027/17 162 | 17.6 |
| ≥75 years | 6535/17 162 | 38.1 |
| Race, n/n (%) | ||
| Caucasian | 11 078/17 162 | 64.5 |
| Hispanic/Latino | 1260/17 162 | 7.3 |
| Afro-Caribbean | 26/17 162 | 0.2 |
| Asian (not Chinese) | 3004/17 162 | 17.5 |
| Chinese | 977/17 162 | 5.7 |
| Mixed/other | 286/17 162 | 1.7 |
| Unwilling to declare/not recorded | 531/17 162 | 3.1 |
| Body mass index, mean (SD) (kg/m2) | 27.8 (5.4) | n/a |
| Pulse, mean (SD) (b.p.m.) | 89.9 (26.7) | n/a |
| Systolic blood pressure, mean (SD) (mmHg) | 133.9 (19.9) | n/a |
| Diastolic blood pressure, mean (SD) (mmHg) | 80.0 (12.7) | n/a |
| Left ventricular ejection fraction <40%, n/n (%) | 973/9744 | 10.0 |
| Type of AF, n/n (%) | ||
| Permanent | 2243/17 160 | 13.1 |
| Persistent | 2679/17 160 | 15.6 |
| Paroxysmal | 4332/17 160 | 25.2 |
| New (newly diagnosed/new onset) | 7906/17 160 | 46.1 |
| Medical history, n/n (%) | ||
| Congestive heart failure | 3532/17 160 | 20.6 |
| Coronary artery disease | 3416/17 160 | 19.9 |
| Acute coronary syndromes | 1614/17 157 | 9.4 |
| Carotid occlusive disease | 507/17 148 | 3.0 |
| Pulmonary embolism or deep vein thrombosis | 478/17 150 | 2.8 |
| Coronary artery bypass graft | 503/16 654 | 3.0 |
| Stroke/transient ischaemic attack | 2186/17 160 | 12.7 |
| Systemic embolism | 109/17 150 | 0.6 |
| History of bleeding | 497/17 149 | 2.9 |
| History of hypertension | 13 396/17 160 | 78.1 |
| Hypercholesterolaemia | 6875/17 153 | 40.1 |
| Diabetes | 3750/17 160 | 21.9 |
| Cirrhosis | 94/17 148 | 0.5 |
| Chronic kidney disease, n/n (%) | ||
| None or mild (Grades I and II) | 15 399/17 159 | 89.7 |
| Moderate to severe (Grades III to V) | 1760/17 159 | 10.3 |
| Dementia | 264/17 153 | 1.5 |
| Alcohol consumption, n/n (%) | ||
| Abstinent/light | 12 980/14 727 | 88.1 |
| Moderate | 1369/14 727 | 9.3 |
| Heavy | 378/14 727 | 2.6 |
| Current/previous smoker, n/n (%) | 5475/15 621 | 35.0 |
| Antithrombotic treatment, n/n (%) | ||
| Vitamin K antagonists | 6334/16 873 | 37.5 |
| Vitamin K antagonists + antiplatelet | 2103/16 873 | 12.5 |
| Factor Xa inhibitors | 637/16 873 | 3.8 |
| Factor Xa inhibitors + antiplatelet | 287/16 873 | 1.7 |
| Direct thrombin inhibitors | 685/16 873 | 4.1 |
| Direct thrombin inhibitors + antiplatelet | 210/16 873 | 1.2 |
| Antiplatelet only | 4627/16 873 | 27.4 |
| None | 1990/16 873 | 11.8 |
| CHA2DS2-VASc score, mean (SD) | 3.3 (1.6) | n/a |
| CHA2DS2-VASc score categories, n/n (%) | ||
| 0 | 381/16 699 | 2.3 |
| 1 | 1965/16 699 | 11.8 |
| 2 | 3220/16 699 | 19.3 |
| 3 | 3988/16 699 | 23.9 |
| 4 | 3681/16 699 | 22.0 |
| 5 | 2020/16 699 | 12.1 |
| 6–9 | 1444/16 699 | 8.6 |
| HAS-BLED score, mean (SD) | 1.5 (0.9) | n/a |
| HAS-BLED score categories, n/n (%) | ||
| 0 | 1463/10 863 | 13.5 |
| 1 | 4428/10 863 | 40.8 |
| 2 | 3542/10 863 | 32.6 |
| 3 | 1217/10 863 | 11.2 |
| 4 | 189/10 863 | 1.7 |
| 5 | 23/10 863 | 0.2 |
| 6–9 | 1/10 863 | <0.1 |
| Care setting speciality at diagnosis, n/n (%) | ||
| Internal medicine | 3378/17 160 | 19.7 |
| Cardiology | 10 614/17 160 | 61.9 |
| Neurology | 375/17 160 | 2.2 |
| Geriatrics | 78/17 160 | 0.5 |
| Primary care/general practice | 2715/17 160 | 15.8 |